137 related articles for article (PubMed ID: 27124705)
1. A case of scurvy associated with nilotinib.
Oak AS; Jaleel T; Fening K; Pavlidakey PG; Sami N
J Cutan Pathol; 2016 Aug; 43(8):725-6. PubMed ID: 27124705
[No Abstract] [Full Text] [Related]
2. Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib.
Shimizu A; Hattori M; Takeuchi Y; Ishikawa O
J Dermatol; 2016 Sep; 43(9):1100-1. PubMed ID: 27028020
[No Abstract] [Full Text] [Related]
3. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
4. Multiple squamous cell carcinomas following introduction of nilotinib.
Peters P; Rabbolini D; Sinnya S; Khosrotehrani K; Wagner G
Clin Exp Dermatol; 2014 Oct; 39(7):791-4. PubMed ID: 25155911
[TBL] [Abstract][Full Text] [Related]
5. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
Cancer Treat Rev; 2012 May; 38(3):241-8. PubMed ID: 21840128
[TBL] [Abstract][Full Text] [Related]
6. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
[TBL] [Abstract][Full Text] [Related]
7. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
Kaune KM; Baumgart M; Gesk S; Mitteldorf C; Baesecke J; Glass B; Haase D; Siebert R; Ghadimi BM; Neumann C; Emmert S
Arch Dermatol; 2008 Mar; 144(3):361-4. PubMed ID: 18347292
[TBL] [Abstract][Full Text] [Related]
8. T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.
Hanley B; Nesr G; Yebra-Fernandez E; Brown L; Rabitsch A; Killeen N; Claudiani S; Milojkovic D; Kanfer E; Apperley J; Naresh KN
J Clin Pathol; 2019 Jul; 72(7):511-512. PubMed ID: 31004076
[No Abstract] [Full Text] [Related]
9. Nilotinib (Tasigna) for CML.
Med Lett Drugs Ther; 2008 Apr; 50(1283):26-7. PubMed ID: 18391899
[No Abstract] [Full Text] [Related]
10. Nilontinib induced keratosis pilaris atrophicans.
Khetarpal S; Sood A; Billings SD
Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617940
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Jarkowski A; Sweeney RP
Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia.
Tokatlı M; Ismayilov R; Erkin Çınar O; Haznedaroğlu İC
Turk J Haematol; 2024 Mar; 41(1):59-60. PubMed ID: 38153228
[No Abstract] [Full Text] [Related]
15. Nilotinib-induced hyperbilirubinemia: is it a negligible adverse event?
Kim MK; Cho HS; Bae YK; Lee KH; Chung HS; Lee SY; Hyun MS
Leuk Res; 2009 Sep; 33(9):e159-61. PubMed ID: 19493567
[No Abstract] [Full Text] [Related]
16. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.
Kitiyakara C; Atichartakarn V
Nephrol Dial Transplant; 2002 Apr; 17(4):685-7. PubMed ID: 11917072
[No Abstract] [Full Text] [Related]
17. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
[No Abstract] [Full Text] [Related]
18. A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
Hansen T; Little AJ; Miller JJ; Ioffreda MD
JAMA Dermatol; 2013 Mar; 149(3):330-2. PubMed ID: 23552567
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
20. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?
Tefferi A
Leukemia; 2013 Sep; 27(9):1939-40. PubMed ID: 23604230
[No Abstract] [Full Text] [Related]
[Next] [New Search]